false
0001888886
True
0001888886
2024-05-09
2024-05-09
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2024-05-09
2024-05-09
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2024-05-09
2024-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2024
Structure Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Cayman Islands |
|
001-41608 |
|
98-1480821 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
601 Gateway Blvd., Suite 900
South San Francisco, California |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
(Registrant’s telephone number, including area code): 650-457-1978
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
|
|
Name Of Each Exchange |
|
|
Title of Each Class |
|
Trading Symbol(s) |
|
On Which Registered |
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share |
|
GPCR |
|
Nasdaq Global Market |
|
|
|
|
|
Ordinary shares, par value $0.0001 per share* |
|
True |
|
Nasdaq Global Market* |
* Not for trading, but only in connection with the registration of
the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2024, Structure Therapeutics Inc. (the “Company”)
issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.
The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
The information in this Current Report on Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated
by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Structure Therapeutics Inc. |
|
|
|
Date: May 9, 2024 |
By: |
/s/ Raymond Stevens |
|
|
Raymond Stevens, Ph.D. |
|
|
Chief Executive Officer |
Exhibit
99.1
Structure Therapeutics Reports First Quarter
2024 Financial Results and Recent Highlights
Topline GSBR-1290 Phase 2a 12-week obesity data
on track for June 2024
Phase 2b study in obesity expected to begin
as planned in the fourth quarter 2024
Plan to initiate dosing in
first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in
June 2024
SAN FRANCISCO
– May 9, 2024 – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company
developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the
first quarter ended March 31, 2024, and highlighted recent corporate achievements.
“We look forward to our 12 week Phase 2a data for GSBR-1290 in
June, and moving forward with our 36 week Phase 2b obesity study later this year,” said Raymond Stevens, Ph.D., Founder and CEO
of Structure Therapeutics. “With tremendous unmet need including more than 100 million people in the United States and more than
800 million people worldwide living with obesity, we believe GSBR-1290 is uniquely positioned as an oral, non-peptide small molecule GLP-1
receptor agonist that can be manufactured at scale and significantly help address the growing obesity epidemic, which current peptide
GLP-1s are not able to do.”
Upcoming Milestones
GSBR-1290 Oral Small Molecule Selective GLP-1R agonist for Obesity
| · | Topline data from the obesity cohort of the Phase 2a study, including full 12-week efficacy data for 40 participants and safety and
tolerability for all 64 participants, are expected in June 2024. |
| · | In preparation for later stage clinical trials, the company is conducting a formulation bridging and titration study to evaluate capsule
versus tablet pharmacokinetics (PK) and explore different titration regimens of GSBR-1290. High level PK study results are expected in
June 2024. |
| · | The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024. |
| · | The Company plans to initiate a Phase 2 study in T2DM in the second half of 2024. |
Oral Small Molecule GLP-1R Combination Programs: Amylin, GIPR,
Apelin (APJR)
| · | Oral Small Molecule Amylin Program: The Company is developing amylin receptor agonists for potential use either alone or in
combination with GLP-1R agonists to treat obesity and associated diseases, and expects to select a development candidate in the fourth
quarter of 2024. |
| · | Oral Small Molecule GIPR Program: The Company is developing a GIPR selective agonist and GLP-1R/GIPR
combinations to treat obesity and associated diseases, and expects to select a development candidate in the first half of 2025. |
| · | Oral Small Molecule Apelin Receptor (APJR) Program: The Company is evaluating ANPA-0073, a Phase 2 ready biased APJR agonist
for potential selective or muscle-sparing weight loss. ANPA-0073 is also being evaluated for idiopathic pulmonary fibrosis (IPF). The
Company has completed a Phase 1 single-ascending and multiple-ascending dose study, in which ANPA-0073 was generally well-tolerated with
no serious adverse event reported. |
Oral Small Molecule LPA1R Program for Idiopathic Pulmonary Fibrosis
(IPF)
| · | The Company is developing LTSE-2578, an oral small molecule antagonist that targets lysophosphatidic
acid 1 receptor (LPA1R). Preclinical studies have demonstrated substantial anti-fibrotic activity in mouse models of fibrotic lung
disease, and the Company expects to initiate a first-in-human study of LTSE-2578 in June 2024. |
First Quarter 2024 Financial Highlights
Cash Position:
Cash, cash equivalents and short-term investments totaled $436.4 million on March 31, 2024. The Company expects its current cash,
cash equivalents and short-term investments to fund projected operations through at least 2026.
R&D
Expenses: Research and development (R&D) expenses for the first quarter of 2024 were $20.7 million, as compared to $13.1
million for the same period in 2023. The increase was primarily due to the advancement of the Company’s GLP-1R franchise and other
research programs, clinical study activities and increases related to employee expenses, primarily due to an increase in personnel.
G&A
Expenses: General and administrative (G&A) expenses for the first quarter of 2024 were $11.3 million, as compared to $6.5
million for the same period in 2023. The increase was primarily due to increases in professional services and employee related expenses
as the Company expanded its infrastructure to drive and support the growth in its operations as a publicly-traded company.
Net Loss:
Net loss for the first quarter of 2024 totaled $26.0 million, with non-cash share-based compensation expense of $2.7 million, compared
to $18.0 million for the first quarter of 2023 with non-cash share-based compensation expense of $2.5 million.
About Structure Therapeutics
Structure
Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small
molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation
structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned
proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide
therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press
release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed
forward-looking statements, including, without limitation, statements concerning the Company’s future plans and prospects, the Company’s
anticipated cash runway, the clinical update from the Company’s Phase 2a study of GSBR-1290 in patients with T2DM and obesity, any
expectations regarding the safety, efficacy or tolerability of GSBR-1290 and other candidates under development, the ability of GSBR-1290
to treat T2DM, obesity or related indications, the planned initiation and study design of the Company’s Phase 2 and Phase 2b studies
of GSBR-1290 in patients with T2DM and obesity and the timing thereof, and first-in-human study of LTSE-2578 and the timing thereof, respectively,
the selection of a development candidate for the Company’s amylin receptor agonist program and GIPR and GLP-1R/GIPR programs, the
planned timing of the Company’s data results and continued development of GSBR-1290, ANPA-0073, amylin, GIPR and next generation
GLP-1R/GIPR combination candidates and expectations regarding an oral development candidate targeting GLP-1R. In addition, when or if
used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions
and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical
facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements
are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results,
levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s
forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related
to the preliminary nature of the results due to length of the study and sample size, the risks that unblinded data is not consistent with
blinded data, the Company’s ability to advance GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic candidates, obtain regulatory
approval of and ultimately commercialize the Company’s therapeutic candidates, the timing and results of preclinical and clinical
trials, the impact of any data collection omissions at any of our clinical sites, the Company’s ability to fund development activities
and achieve development goals, the impact of any global pandemics, inflation, supply chain issues, rising interest rates and future bank
failures on the Company’s business, its ability to protect its intellectual property and other risks and uncertainties described
in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, as filed with the SEC on March 8, 2024, and future reports the Company may file
with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they
were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by
law.
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Statements of Operations
(unaudited)
(In thousands, except per share amounts)
| |
THREE MONTHS ENDED | |
| |
MARCH 31, | |
| |
2024 | | |
2023 | |
Operating expenses: | |
| | | |
| | |
Research and development | |
$ | 20,679 | | |
$ | 13,135 | |
General and administrative | |
| 11,336 | | |
| 6,514 | |
Total operating expenses | |
| 32,015 | | |
| 19,649 | |
Loss from operations | |
| (32,015 | ) | |
| (19,649 | ) |
Interest and other income (expense), net | |
| 6,008 | | |
| 1,699 | |
Loss before provision for income taxes | |
| (26,007 | ) | |
| (17,950 | ) |
Provision for income taxes | |
| 29 | | |
| 25 | |
Net loss | |
$ | (26,036 | ) | |
$ | (17,975 | ) |
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Balance Sheet Data
(unaudited)
(In thousands)
| |
MARCH 31, | | |
DECEMBER 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash, cash equivalents and short-term investments | |
$ | 436,449 | | |
$ | 467,323 | |
Prepaid expenses and other current assets | |
| 12,911 | | |
| 6,285 | |
Total current assets | |
| 449,360 | | |
| 473,608 | |
Property and equipment, net | |
| 3,120 | | |
| 3,228 | |
Operating right-of-use assets | |
| 4,698 | | |
| 5,136 | |
Other non-current assets | |
| 47 | | |
| 45 | |
Total assets | |
$ | 457,225 | | |
$ | 482,017 | |
Liabilities and shareholders’ equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 6,538 | | |
$ | 4,742 | |
Accrued expenses and other current liabilities | |
| 15,448 | | |
| 18,558 | |
Operating lease liabilities, current portion | |
| 1,600 | | |
| 1,440 | |
Total current liabilities | |
| 23,586 | | |
| 24,740 | |
Operating lease liabilities, net of current portion | |
| 3,525 | | |
| 4,013 | |
Other non-current liabilities | |
| 296 | | |
| 298 | |
Total liabilities | |
| 27,407 | | |
| 29,051 | |
Total shareholders’ equity | |
| 429,818 | | |
| 452,966 | |
Total liabilities and shareholders’ equity | |
$ | 457,225 | | |
$ | 482,017 | |
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
v3.24.1.u1
Cover
|
May 09, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 09, 2024
|
Entity File Number |
001-41608
|
Entity Registrant Name |
Structure Therapeutics Inc.
|
Entity Central Index Key |
0001888886
|
Entity Tax Identification Number |
98-1480821
|
Entity Incorporation, State or Country Code |
E9
|
Entity Address, Address Line One |
601 Gateway Blvd.
|
Entity Address, Address Line Two |
Suite 900
|
Entity Address, City or Town |
South San Francisco
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94080
|
City Area Code |
650
|
Local Phone Number |
457-1978
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
American Depositary Shares Adss Each Representing Three Ordinary Shares Par Value 0. 0001 Per Ordinary Share [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share
|
Trading Symbol |
GPCR
|
Security Exchange Name |
NASDAQ
|
Ordinary Shares Par Value 0. 0001 Per Share [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Ordinary shares, par value $0.0001 per share*
|
No Trading Symbol Flag |
true
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
+ References
+ Details
Name: |
dei_NoTradingSymbolFlag |
Namespace Prefix: |
dei_ |
Data Type: |
dei:trueItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=gpcr_AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=gpcr_OrdinarySharesParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From May 2023 to May 2024